Background Antithrombotic therapy reduces stroke, embolism and mortality in patients with
atrial fibrillation (AF); however, meta-analyses have focused on pairwise comparisons of …

BACKGROUND: The ARISTOTLE trial demonstrated that apixaban had significantly lower
rates of stroke/systemic embolism (SE) and major bleeding than warfarin; however, no direct …

Background: Real-world, observational studies have investigated the safety profile of Direct
Oral Anticoagulants (DOACs) on Major Hemorrhage (MH) used for stroke prevention in Non …

Objectives. We conducted a systematic review and network meta-analysis of randomized
controlled trials (RCTs) including the comparison of non-vitamin K antagonist oral …

Background: The risk of bleeding and stroke/systemic embolism (SE) events associated with
apixaban vs. warfarin among oral anticoagulant-naïve Japanese patients with non-valvular …

Background: Recent observational studies have compared effectiveness and safety profiles
between non-vitamin K antagonist oral anticoagulants (NOACs) and warfarin in patients with …

Background: Direct oral anticoagulants (DOACs) have widely replaced warfarin for stroke
prevention in nonvalvular atrial fibrillation. Our objective was to compare the safety and …

There is no direct evidence comparing the 2 most commonly prescribed direct oral
anticoagulants, apixaban and rivaroxaban, used for stroke prevention in nonvalvular atrial …

Objective To study the effectiveness and safety of the non-vitamin K antagonist oral
anticoagulants (novel oral anticoagulants, NOACs) dabigatran, rivaroxaban, and apixaban …

Introduction Apixaban and rivaroxaban are the most commonly used direct oral
anticoagulants (DOACs) for atrial fibrillation (AF) and venous thromboembolism (VTE). Both …